

Global Cell and Gene Therapy Market: Focus on Products, Applications, Regions and Competitive Landscape – Analysis and Forecast, 2019-2025

<https://marketpublishers.com/r/G3B3F179AD34EN.html>

Date: July 2019

Pages: 243

Price: US\$ 5,000.00 (Single User License)

ID: G3B3F179AD34EN

Abstracts

Hard copy option is available on any of the options above at an additional charge of \$500. Please email us at order@marketpublishers.com with your request.

Key Questions Answered in this Report:

What are the major market drivers, challenges, and opportunities in the global cell and gene therapy market?

What are the underlying structures resulting in the emerging trends within the global cell and gene therapy market?

How is each segment of the global cell and gene therapy market expected to grow during the forecast period and what is the estimated revenue to be generated by each of the segments by the end of 2025?

What is the expected compound growth rate to be witnessed by the leading players in the market during the forecast period 2019-2025?

What are the key applications in global cell and gene therapy market? What are the major segments of these applications?

Who are the key manufacturers and service providers in the global cell and gene therapy market, and what are their contributions?

Global Cell and Gene Therapy Market Forecast, 2019-2025

The cell and gene therapy Industry analysis by BIS Research projects the market to grow at a significant CAGR of 36.52% during the forecast period, 2019-2025. The cell and gene therapy market generated \$1,017.2 million revenue in 2018, in terms of value.

The cell and gene therapy growth has been primarily attributed to the major drivers in this market such as increasing prevalence of cancer and chronic diseases, rising number of clinical trials for cell and gene therapy, steady investment and consolidation in the cell and gene therapy market and favorable regulatory environment. The market is expected to grow at a significant growth rate due to the opportunities that lie within its domain, which include drug approvals and strong pipeline of cell and gene therapies. However, there are significant challenges which are restraining the market growth. These challenges include high cost of therapy and lack of therapy specific assays.

Expert Quote on the Cell and Gene Therapy Market

“The CAR-TCR drug development field has achieved huge success over the past year with regulatory approval in the U.S., Europe, Japan and Australia proving the potential these drugs have to successfully cure patients around the globe.”

Scope of the Market Intelligence on Cell and Gene Therapy Market

The cell and gene therapy market research provides a holistic view of the cell and gene therapy market in terms of various factors influencing it, including regulatory reforms, and technological advancements.

The scope of this report is centered upon conducting a detailed study of the products and services allied with the therapeutics market. In addition, the study also includes exhaustive information on the unmet needs, perception on the new products, competitive landscape, market share of leading manufacturers, growth potential of each underlying sub-segment, and company, as well as other vital information with respect to global cell and gene therapy market.

Market Segmentation

The cell and gene therapy market segmentation (on the basis of cell and gene therapy manufacturing) is further segmented into upstream manufacturing, and downstream manufacturing.

The cell and gene therapy market segmentation (on the basis of product) is segmented into therapeutic market and pipeline analysis.

The cell and gene therapy market segmentation (on the basis of therapeutic class) is segmented into oncology, hematology, cardiovascular, ophthalmology, neurology, and other applications.

Key Companies in the Cell and Gene Therapy Industry

The key manufacturers who have been contributing significantly to the cell and gene therapy market include Amgen Inc., bluebird bio, Inc. Dendreon Pharmaceuticals LLC., Fibrocell Science, Inc., Human Stem Cell Institute, Kite Pharma, Inc., Kolon TissueGene, Inc., Novartis AG, Orchard Therapeutics plc., Organogenesis Holdings Inc., Pfizer, Inc., Spark Therapeutics, Inc., Vericel Corporation, and ViroMed Co., Ltd., among others.

Contents

1 RESEARCH SCOPE AND METHODOLOGY

- 1.1 Scope of the Study
- 1.2 Research Methodology
- 1.3 Data Sources
- 1.4 Assumptions and Limitations
- 1.5 Data and Prediction Modelling

2 GLOBAL CELL AND GENE THERAPY MARKET: GLOBAL PROSPECTIVE

- 2.1 Introduction
- 2.2 Cell and Gene Therapy and Their Clinical Importance
- 2.3 Cell and Gene Therapy Development and Commercialization Landscape
- 2.4 Global Cell and Gene Therapy Market Size, 2018-2025
- 2.5 Role of Regulatory Bodies and Consortium in Cell and Gene Therapy
- 2.6 Reimbursement and Market Access
- 2.7 Key Companies in Cell and Gene Therapy Market and their Contributions

3 GLOBAL CELL AND GENE THERAPY MARKET OVERVIEW (ADDRESSABLE MARKET SIZE AND GROWTH POTENTIAL), 2018-2025

- 3.1 Cell and Gene Therapy Industry
- 3.2 Key Successful Cell and Gene Therapy Commercialization
- 3.3 Addressable Market and Growth Potential
- 3.4 North America
- 3.5 Europe
- 3.6 Asia-Pacific
- 3.7 Latin America
- 3.8 Rest-of-the-World

4 INDUSTRY INSIGHTS

- 4.1 Mergers and Acquisitions
- 4.2 Product Approvals
- 4.3 Partnerships, Collaborations and Joint Ventures
- 4.4 Business Expansion Activities and Others
- 4.5 Legal Requirements and Regulations

4.5.1 Overview of Regulatory Pathway for Cell and Gene Therapy

4.5.2 FDA Expedited Approval Designations

4.5.2.1 Fast Track Designation:

4.5.2.2 Breakthrough Therapy:

4.5.2.3 Accelerated Approval:

4.5.2.4 Priority Review:

4.5.2.5 Regenerative Medicine Advanced Therapy Designation:

4.5.3 Expedited Designation Vs. Traditional Approval Timelines:

4.5.4 Regulatory Challenges:

4.5.5 Successful Regulatory Strategies

5 PATENT LANDSCAPE

6 CELL AND GENE THERAPY MANUFACTURING

6.1 Viral Vector Manufacturing

6.1.1 Upstream Manufacturing

6.1.1.1 Cost Consideration and Timelines

6.1.1.2 Process Design and Regulatory Burdens

6.1.1.3 Other Considerations

6.1.1.4 Viral vector Manufacturing

6.1.1.4.1 Retrovirus

6.1.1.4.2 Lentivirus

6.1.1.4.3 AAV

6.1.1.4.4 Adenovirus

6.1.2 Downstream Manufacturing

6.1.2.1 Viral Vector Manufacturing

6.1.2.1.1 Retrovirus

6.1.2.1.2 Lentivirus

6.1.2.1.3 AAV

6.1.2.1.4 Adenovirus

6.1.2.2 Cost Considerations and Timelines

6.1.2.3 Challenges in Downstream

6.1.2.4 Scale-up of Downstream from Research to Clinical Manufacturing

6.2 Non-Viral Vector Manufacturing

6.2.1 Non-Viral, Plasmid-Free Manufacturing

6.2.2 Plasmid

6.2.3 Naked DNA

6.2.4 Physical-Mediated Methods

6.3 Cell and Gene Therapy Manufacturing Capacity, by Company

7 MARKET DYNAMICS

7.1 Impact Analysis

7.2 Market Drivers

7.2.1 Increasing Prevalence of Cancer and Chronic Diseases

7.2.2 Rising Number of Clinical Trials

7.2.3 Steady Investment and Consolidation in the Cell and Gene Therapy Market

7.2.4 Favorable Regulatory Environment

7.3 Market Restraints

7.3.1 Lack of Reliable Vector Production for Cell and Gene Therapy

7.4 Opportunities

7.4.1 Drug Approvals and Strong Pipeline of Cell and Gene Therapies

7.5 Market Challenges

7.5.1 High Cost of Therapy

7.5.2 Lack of Therapy Specific Assays

8 GLOBAL CELL AND GENE THERAPY MARKET (BY PRODUCT)

8.1 Therapeutic Market

8.1.1 Yescarta

8.1.2 Provenge

8.1.3 Luxturna

8.1.4 Kymriah

8.1.5 Imlygic

8.1.6 Gintuit

8.1.7 MACI

8.1.8 Laviv

8.1.9 Gendicine

8.1.10 Oncorine

8.1.11 Neovasculgen

8.1.12 Strimvelis

8.1.13 Invossa

8.1.14 Others

8.2 Pipeline Analysis

8.2.1 Phase

8.2.2 Phase

8.2.3 Phase

8.2.4 Phase

9 GLOBAL CELL AND GENE THERAPY MARKET (BY THERAPEUTIC CLASS)

9.1 Rare Diseases

9.2 Oncology

9.3 Hematology

9.4 Cardiovascular

9.5 Ophthalmology

9.6 Neurology

9.7 Other Therapeutic Classes

10 GLOBAL CELL AND GENE THERAPY MARKET (BY REGION), 2018-2025 (\$MILLION)

10.1 Overview

10.2 North America

10.2.1 U.S.

10.2.1.1 Approved Products

10.2.1.2 Market Size and Forecast

10.2.1.3 Key Developments

10.2.1.4 Competitive landscape

10.2.2 Canada

10.2.2.1 Approved Products

10.2.2.2 Market Size and Forecast

10.2.2.3 Key Developments

10.2.2.4 Competitive landscape

10.3 Europe

10.3.1 Germany

10.3.1.1 Approved Products

10.3.1.2 Market Size and Forecast

10.3.1.3 Key Developments

10.3.1.4 Competitive landscape

10.3.2 France

10.3.2.1 Approved Products

10.3.2.2 Market Size and Forecast

10.3.2.3 Key Developments

10.3.2.4 Competitive landscape

10.3.3 U.K.

- 10.3.3.1 Approved Products
- 10.3.3.2 Market Size and Forecast
- 10.3.3.3 Competitive landscape
- 10.3.4 Italy
 - 10.3.4.1 Approved Products
 - 10.3.4.2 Market Size and Forecast
 - 10.3.4.3 Key Developments
- 10.3.5 Spain
 - 10.3.5.1 Approved Products
 - 10.3.5.2 Market Size and Forecast
 - 10.3.5.3 Key Developments
 - 10.3.5.4 Competitive landscape
- 10.3.6 The Netherlands
 - 10.3.6.1 Approved Products
 - 10.3.6.2 Market Size and Forecast
 - 10.3.6.3 Key Developments
 - 10.3.6.4 Competitive landscape
- 10.3.7 Russia
 - 10.3.7.1 Approved Products
 - 10.3.7.2 Market Size and Forecast
 - 10.3.7.3 Competitive landscape
- 10.3.8 Rest-of-Europe
 - 10.3.8.1 Market Size and Forecast
 - 10.3.8.2 Key Developments
- 10.4 Asia-Pacific
 - 10.4.1 Japan
 - 10.4.1.1 Approved Products
 - 10.4.1.2 Market Size and Forecast
 - 10.4.1.3 Key Developments
 - 10.4.1.4 Competitive landscape
 - 10.4.1.5 China
 - 10.4.1.6 Approved Products
 - 10.4.1.7 Market Size and Forecast
 - 10.4.1.8 Key Developments
 - 10.4.1.9 Competitive landscape
 - 10.4.2 Australia
 - 10.4.2.1 Approved Products
 - 10.4.2.2 Market Size and Forecast
 - 10.4.2.3 Key Developments

10.4.3 South Korea

10.4.3.1 Approved Products

10.4.3.2 Market Size and Forecast

10.4.3.3 Key Developments

10.4.3.4 Competitive landscape

10.4.4 India

10.4.4.1 Approved Products

10.4.4.2 Market Size and Forecast

10.4.4.3 Competitive landscape

10.4.5 Singapore

10.4.5.1 Approved Products

10.4.5.2 Market Size and Forecast

10.4.5.3 Key Developments

10.4.6 Rest-of-Asia-Pacific

10.4.6.1 Market Size and Forecast

10.4.6.2 Key Developments

10.5 Latin America

10.5.1 Brazil

10.5.1.1 Market Size and Forecast

10.5.2 Mexico

10.5.2.1 Market Size and Forecast

10.5.3 Rest-of-Latin America

10.5.3.1 Market Size and Forecast

10.6 Rest-of-World

10.6.1.1 Market Size and Forecast

11 COMPETITIVE LANDSCAPE

11.1 Market Share Analysis

11.2 Growth Share Analysis

12 COMPANY PROFILES

12.1 Overview

12.2 Amgen Inc.

12.2.1 Company Overview

12.2.2 Role of Amgen Inc. in the Global Cell and Gene Therapy Market

12.2.3 Financials

12.2.4 Key Insights about Financial Health of the Company

- 12.2.5 SWOT Analysis
- 12.3 bluebird bio, Inc.
 - 12.3.1 Company Overview
 - 12.3.2 Role of bluebird bio, Inc. in the Global Cell and Gene Therapy Market
 - 12.3.3 Financials
 - 12.3.4 Key Insights about Financial Health of the Company
 - 12.3.5 SWOT Analysis
- 12.4 Dendreon Pharmaceuticals LLC.
 - 12.4.1 Company Overview
 - 12.4.2 Role of Dendreon Pharmaceuticals LLC. in the Global Cell and Gene Therapy Market
 - 12.4.3 SWOT Analysis
- 12.5 Fibrocell Science, Inc.
 - 12.5.1 Company Overview
 - 12.5.2 Role of Fibrocell Science, Inc. in the Global Cell and Gene Therapy Market
 - 12.5.3 Key Insights about Financial Health of the Company
 - 12.5.4 SWOT Analysis
- 12.6 Human Stem Cells Institute
 - 12.6.1 Company Overview
 - 12.6.2 Role of Human Stem Global Cell and Gene Therapy Cell Market
 - 12.6.3 SWOT Analysis
- 12.7 Kite Pharma, Inc.
 - 12.7.1 Company Overview
 - 12.7.2 Role of Kite Pharma, Inc. in the Global Cell and Gene Therapy Market
 - 12.7.3 Financials
 - 12.7.4 Key Insights about Financial Health of the Company
 - 12.7.5 SWOT Analysis
- 12.8 Kolon TissueGene, Inc.
 - 12.8.1 Company Overview
 - 12.8.2 Role of Kolon TissueGene, Inc. in the Global Cell and Gene Therapy Market
 - 12.8.3 SWOT Analysis
- 12.9 Novartis AG
 - 12.9.1 Company Overview
 - 12.9.2 Role of Novartis AG in the Global Cell and Gene Therapy Market
 - 12.9.3 Financials
 - 12.9.4 SWOT Analysis
- 12.10 Orchard Therapeutics plc.
 - 12.10.1 Company Overview
 - 12.10.2 Role of Orchard Therapeutics plc. in the Global Cell and Gene Therapy Market

- 12.10.3 Financials
- 12.10.4 SWOT Analysis
- 12.11 Organogenesis Holdings Inc.
 - 12.11.1 Company Overview
 - 12.11.2 Role of Organogenesis Holdings Inc. in the Global Cell and Gene Therapy Market
 - 12.11.3 SWOT Analysis
- 12.12 Pfizer, Inc.
 - 12.12.1 Company Overview
 - 12.12.2 Role of Pfizer, Inc. in the Global Cell and Gene Therapy Market
 - 12.12.3 Financials
 - 12.12.4 Key Insights about Financial Health of the Company
 - 12.12.5 SWOT Analysis
- 12.13 RENOVA THERAPEUTICS
 - 12.13.1 Company Overview
 - 12.13.2 Role of RENOVA THERAPEUTICS in the Global Cell and Gene Therapy Market
 - 12.13.3 SWOT Analysis
- 12.14 Shanghai Sunway Biotech Co., Ltd.,
 - 12.14.1 Company Overview
 - 12.14.2 Role of Shanghai Sunway Biotech Co., Ltd., in the Global Cell and Gene Therapy Market
 - 12.14.3 SWOT Analysis
- 12.15 Sibiono GeneTech Co. Ltd.,
 - 12.15.1 Company Overview
 - 12.15.2 Role of Sibiono GeneTech Co. Ltd., in the Global Cell and Gene Therapy Market
 - 12.15.3 SWOT Analysis
- 12.16 Spark Therapeutics, Inc.
 - 12.16.1 Company Overview
 - 12.16.2 Role of Spark Therapeutics, Inc. in the Global Cell and Gene Test Market
 - 12.16.3 Financials
 - 12.16.4 Key Insights about Financial Health of the Company
 - 12.16.5 SWOT Analysis
- 12.17 Vericel Corporation
 - 12.17.1 Company Overview
 - 12.17.2 Role of Vericel Corporation in the Global Cell and Gene Therapy Market
 - 12.17.3 Financials
 - 12.17.4 Key Insights About Financial Health of the Company
 - 12.17.5 SWOT Analysis

12.18 ViroMed Co., Ltd.

12.18.1 Company Overview

12.18.2 Role of ViroMed Co., Ltd. in the Global Cell and Gene Therapy Market

12.18.3 Financials

12.18.4 SWOT Analysis

List Of Tables

LIST OF TABLES

Table 2.1: Approved gene therapies worldwide, October 2018

Table 2.2: Product Class Inclusions in EU and US Regulatory Pathway

Table 2.3: Key Market Access Landscape (9 Countries), January 2019

Table 2.4: Key Companies in Cell and Gene Therapy Market, 2018

Table 3.1: Key Products of Cell and Gene Therapy Market

Table 6.1: Key Viral Vectors

Table 6.2: Cell and Gene Therapy Manufacturing Capacity, by Company

Table 7.1: Impact Analysis

Table 7.2: Key Cell and Gene Therapies with FDA Expedited Review

Table 8.1: List of key Cell/Gene Therapy Products with Marketing Authorization (MA)

Table 8.2: Key Cell and Gene Therapy Drugs in Phase 3, 2018

Table 9.1: List of Cell and Gene Therapy Medicines in Development (As of November 2018)

Table 10.1: List of Cell and Gene Therapy Products with Marketing Authorization in the European Union by EMA

List Of Figures

LIST OF FIGURES

Figure 1: Impact of Market Drivers and Market Challenges on the Global Cell and Gene Therapy Market

Figure 2: Global Cell and Gene Therapy Market Snapshot

Figure 3: Dominant Segments of the Global Cell and Gene Therapy Market, 2019 and 2025

Figure 4: Global Cell and Gene Therapy Market (by Approved Product), 2019 and 2025

Figure 5: Global Cell and Gene Therapy Market (by Therapeutic Class), 2019 and 2025

Figure 6: Global Cell and Gene Therapy Market (by Region), 2019 and 2025

Figure 1.1: Global Cell and Gene Therapy Market Segmentation

Figure 1.2: Global Cell and Gene Therapy Market Research Methodology

Figure 1.3: Global Cell and Gene Therapy Market Research Methodology Approach

Figure 1.4: Primary Research

Figure 1.5: Secondary Research

Figure 1.6: Data Triangulation

Figure 1.7: Bottom-Up Approach (Segment-Wise Analysis)

Figure 1.8: Top-Down Approach (Segment-Wise Analysis)

Figure 1.9: Assumptions and Limitations

Figure 1.10: Considered Factors for Data Prediction and Modelling

Figure 2.1: Clinical Trials by Therapeutic Category, Cell and Gene Therapy, 2018

Figure 2.2: Global Cell and Gene Therapy Market Size, 2018-2025

Figure 3.1: Addressable Market Size of Commercialized Products, 2018

Figure 3.2: Addressable Market Size of Commercialized Products, 2025

Figure 3.3: North America Cell and Gene Therapy Addressable Market, 2018 and 2025

Figure 3.4: Europe Cell and Gene Therapy Addressable Market, 2018 and 2025

Figure 3.5: Asia-Pacific Cell and Gene Therapy Addressable Market, 2018 and 2025

Figure 3.6: Latin America Cell and Gene Therapy Addressable Market 2019 and 2025

Figure 4.1: Product Approvals Share (by Company), January 2016 – April 2019

Figure 4.2: Synergistic Activities Share (by Company), January 2016 – April 2019

Figure 5.1: Share of Patents (by Ownership), 2016-2019

Figure 7.1: Number of Active and Completed Clinical Trials for Cell and Gene Therapy, by Start Date (2014-2018)

Figure 8.1: Global Cell and Gene Therapy Market, by Therapeutic Drugs, 2018-2025

Figure 8.2: Global Revenue for Yescarta, 2018-2025

Figure 8.3: Global Revenue for Provenge, 2018-2025

Figure 8.4: Global Revenue for Luxturna, 2018-2025

- Figure 8.5: Global Revenue for Kymriah, 2018-2025
- Figure 8.6: Global Revenue for Imlygic, 2018-2025
- Figure 8.7: Global Revenue for MACI, 2018-2025
- Figure 8.8: Global Revenue for Gendicine, 2018-2025
- Figure 8.9: Global Revenue for Oncorine, 2018-2025
- Figure 8.10: Global Revenue for Neovasculogen, 2018-2025
- Figure 8.11: Global Revenue for Strimvelis, 2018-2025
- Figure 8.12: Global Revenue for Invossa, 2018-2025
- Figure 8.13: Global Revenue for Other Drugs, 2018-2025
- Figure 8.14: Cell and Gene Therapy Medicines in Development by Disease, 2018
- Figure 8.15: Cell and Gene Therapy: Breakdown of Pipeline, 2017
- Figure 8.16: Number of Phase 1 Clinical Trials for Cell and Gene Therapy, 2014-2018
- Figure 8.17: Number of Phase 2 Clinical Trials for Cell and Gene Therapy, 2014-2018
- Figure 8.18: Global Cell and Gene Therapy Market, By Late Phase, 2018-2025
- Figure 9.1: Global Cell and Gene Therapy Market, By Rare Diseases, 2018-2025
- Figure 9.2: Global Cell and Gene Therapy Market, By Oncology, 2018-2025
- Figure 9.3: Global Cell and Gene Therapy Market, By Hematology, 2018-2025
- Figure 9.4: Global Cell and Gene Therapy Market, By Cardiovascular Disease, 2018-2025
- Figure 9.5: Global Cell and Gene Therapy Market, By Ophthalmology, 2018-2025
- Figure 9.6: Global Cell and Gene Therapy Market, By Neurology, 2018-2025
- Figure 9.7: Global Cell and Gene Therapy Market, By Other Therapeutic Class, 2018-2025
- Figure 10.1: Global Cell and Gene Therapy Market (by Region), 2019 and 2025
- Figure 10.2: North America Cell and Gene Therapy Market, 2018-2025
- Figure 10.3: North America-Market Dynamics
- Figure 10.4: U.S. Cell and Gene Therapy Market, 2018-2025
- Figure 10.5: Projections of the Older Adult Population in the U.S.: 2020 to 2060 (Million)
- Figure 10.6: Canada Cell and Gene Therapy Market, 2018-2025
- Figure 10.7: Europe Cell and Gene Therapy Market, 2018-2025
- Figure 10.8: Europe-Market Dynamics
- Figure 10.9: Germany Cell and Gene Therapy Market, 2018-2025
- Figure 10.10: France Cell and Gene Therapy Market, 2018-2025
- Figure 10.11: The U.K. Cell and Gene Therapy Market, 2018-2025
- Figure 10.12: Italy Cell and Gene Therapy Market, 2018-2025
- Figure 10.13: Spain Cell and Gene Therapy Market, 2018-2025
- Figure 10.14: The Netherlands Cell and Gene Therapy Market, 2018-2025
- Figure 10.15: Russia Cell and Gene Therapy Market, 2018-2025
- Figure 10.16: Rest-of-Europe Cell and Gene Therapy Market, 2018-2025

- Figure 10.17: Europe Cell and Gene Therapy Market, 2018-2025
- Figure 10.18: Asia-Pacific Market Dynamics
- Figure 10.19: Japan Cell and Gene Therapy Market, 2018-2025
- Figure 10.20: China Cell and Gene Therapy Market, 2018-2025
- Figure 10.21: Australia Cell and Gene Therapy Market, 2018-2025
- Figure 10.22: S. Korea Cell and Gene Therapy Market, 2018-2025
- Figure 10.23: India Cell and Gene Therapy Market, 2018-2025
- Figure 10.24: Singapore Cell and Gene Therapy Market, 2018-2025
- Figure 10.25: Rest-of-Asia-Pacific Cell and Gene Therapy Market, 2018-2025
- Figure 10.26: Latin America Cell and Gene Therapy Market, 2018-2025
- Figure 10.27: Latin America: Market Dynamics
- Figure 10.28: Brazil Cell and Gene Therapy Market, 2018-2025
- Figure 10.29: Mexico Cell and Gene Therapy Market, 2018-2025
- Figure 10.30: Rest-of-Latin America Cell and Gene Therapy Market, 2018-2025
- Figure 10.31: Rest-of-World Cell and Gene Therapy Market, 2018-2025
- Figure 11.1: Market Share Analysis for the Global Cell and Gene Therapy Market, 2018
- Figure 11.2: Growth Share Matrix for Global Cell and Gene Therapy Market (by Company), 2018
- Figure 12.1: Total Number of Companies Profiled
- Figure 12.2: Amgen Inc.: Overall Product Portfolio
- Figure 12.3: Amgen Inc.: Pipeline Product Portfolio
- Figure 12.4: Amgen Inc.: Overall Financials, 2016-2018
- Figure 12.5: Amgen Inc.: Revenue (by Region), 2016-2018
- Figure 12.6: Amgen Inc.: R&D Expenditure, 2016-2018
- Figure 12.7: Amgen Inc.: SWOT Analysis
- Figure 12.8: Pipeline Product Portfolio: bluebird bio, Inc.
- Figure 12.9: bluebird bio, Inc.: Overall Financials, 2016-2018
- Figure 12.10: bluebird bio, Inc.: R&D Expenditure, 2016-2018
- Figure 12.11: bluebird bio, Inc.: SWOT Analysis
- Figure 12.12: Dendreon Pharmaceuticals LLC: Product Portfolio
- Figure 12.13: Dendreon Pharmaceuticals LLC.: SWOT Analysis
- Figure 12.14: Fibrocell Science, Inc.: Overall Product Portfolio
- Figure 12.15: Fibrocell Science, Inc.: Pipeline Product Portfolio
- Figure 12.16: Fibrocell Science, Inc.: R&D Expenditure, 2016-2018
- Figure 12.17: Fibrocell Science, Inc.: SWOT Analysis
- Figure 12.18: Human Stem Cell Institute: Overall Product Portfolio
- Figure 12.19: Human Stem Cell Institute: SWOT Analysis
- Figure 12.20: Kite Pharma, Inc.: Overall Product Portfolio
- Figure 12.21: Kite Pharma, Inc.: Pipeline Product Portfolio

Figure 12.22: Kite Pharma, Inc.: Overall Financials, 2016-2018
Figure 12.23: Kite Pharma, Inc.: R&D Expenditure, 2016-2018
Figure 12.24: Kite Pharma, Inc.: SWOT Analysis
Figure 12.25: Kolon TissueGene, Inc.: Pipeline Product Portfolio
Figure 12.26: Kolon TissueGene, Inc.: SWOT Analysis
Figure 12.27: Novartis AG: Overall Product Portfolio
Figure 12.28: Novartis AG: Pipeline Product Portfolio
Figure 12.29: Novartis AG: Overall Financials, 2016-2018
Figure 12.30: Novartis AG: Revenue (by Business Segment), 2016-2018
Figure 12.31: Novartis AG: SWOT Analysis
Figure 12.32: Orchard Therapeutics plc.: Pipeline Product Portfolio
Figure 12.33: Orchard Therapeutics plc.: Overall Financials, 2016-2018
Figure 12.34: Orchard Therapeutics plc: SWOT Analysis
Figure 12.35: Organogenesis Holdings Inc.: Overall Product Portfolio
Figure 12.36: Organogenesis Holdings Inc.: SWOT Analysis
Figure 12.37: Pfizer, Inc.: Pipeline Product Portfolio
Figure 12.38: Pfizer, Inc.: Overall Financials, 2016-2018
Figure 12.39: Pfizer, Inc.: Revenue (by Region), 2016-2018
Figure 12.40: Pfizer, Inc.: R&D Expenditure, 2016-2018
Figure 12.41: Pfizer, Inc.: SWOT Analysis
Figure 12.42: RENOVA THERAPEUTICS: Pipeline Product Portfolio
Figure 12.43: RENOVA THERAPEUTICS: SWOT Analysis
Figure 12.44: Product Portfolio: Shanghai Sunway Biotech Co., Ltd.,
Figure 12.45: Shanghai Sunway Biotech Co., Ltd.: SWOT Analysis
Figure 12.46: Sibiono GeneTech Co. Ltd.: Overall Product Portfolio
Figure 12.47: Sibiono GeneTech Co. Ltd.: SWOT Analysis
Figure 12.48: Spark Therapeutics, Inc.: Overall Product Portfolio
Figure 12.49: Spark Therapeutics, Inc.: Pipeline Product Portfolio
Figure 12.50: Spark Therapeutics, Inc.: Overall Financials, 2015-2017
Figure 12.51: Spark Therapeutics, Inc.: R&D Expenditure, 2015-2017
Figure 12.52: Spark Therapeutics, Inc.: SWOT Analysis
Figure 12.53: Vericel Corporation: Overall Product Portfolio
Figure 12.54: Vericel Corporation: Pipeline Product Portfolio
Figure 12.55: Vericel Corporation: Overall Financials, 2016-2018
Figure 12.56: Vericel Corporation: Revenue (by Product), 2016-2018
Figure 12.57: Vericel Corporation: R&D Expenditure (2016-2018)
Figure 12.58: Vericel Corporation: SWOT Analysis
Figure 12.59: ViroMed Co., Ltd.: Pipeline Product Portfolio
Figure 12.60: ViroMed Co: Overall Financials, 2016-2018

Figure 12.61: ViroMed Co., Ltd.: SWOT Analysis

I would like to order

Product name: Global Cell and Gene Therapy Market: Focus on Products, Applications, Regions and Competitive Landscape – Analysis and Forecast, 2019-2025

Product link: <https://marketpublishers.com/r/G3B3F179AD34EN.html>

Price: US\$ 5,000.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/G3B3F179AD34EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970

